Synapse
⌘+K
Sign In
Sign Up for Free
Synapse
Sign In
Sign Up for Free
Home
Communities
Explore
More
Language
English
English
Glaceum (South Korea)
h-index: 4
Total citations: 77
Total papers: 21
Homepage:
http://glaceum.com/
Recent papers from Glaceum (South Korea)
Vutiglabridin overcomes the GLP-1 RA-associated weight-loss plateau to achieve normal body weight
International Journal of Obesity · 2026
Paraoxonase 2 as a target for aging-related diseases.
2026
Vutiglabridin ameliorates obesity by directly reducing fat mass through AMPK/lipophagy activation in adipocytes
Biomedicine & Pharmacotherapy · 2025
Vutiglabridin ameliorates obesity by directly reducing fat mass through AMPK/lipophagy activation in adipocytes
Biomedicine & Pharmacotherapy · 2025
Targeting PON2 with Vutiglabridin Restores Mitochondrial Integrity and Attenuates Oxidative Stress-Induced Senescence
Antioxidants · 2025
Neurotherapeutic effects of Vutiglabridin as a Paraoxonase-2 modulator in preclinical models of Parkinson’s disease
Molecular Neurodegeneration · 2025
Paraoxonase‐2 agonist vutiglabridin promotes autophagy activation and mitochondrial function to alleviate non‐alcoholic steatohepatitis
British Journal of Pharmacology · 2024
Effects of meal type on the bioavailability of vutiglabridin, a novel anti‐obesity agent, in healthy subjects
Clinical and Translational Science · 2024
Vutiglabridin Alleviates Cellular Senescence with Metabolic Regulation and Circadian Clock in Human Dermal Fibroblasts
Antioxidants · 2024
Vutiglabridin exerts anti-ageing effects in aged mice through alleviating age-related metabolic dysfunctions
Experimental Gerontology · 2023
Effect of anti-obesity agent HSG4112 on overweight and obese patients following 12 weeks of oral treatment: a study protocol for a randomised, double-blind, placebo-controlled, parallel-group, phase 2a clinical trial
Frontiers in Pharmacology · 2023
Preclinical Bioavailability Assessment of a Poorly Water-Soluble Drug, HGR4113, Using a Stable Isotope Tracer
Pharmaceutics · 2023
Vutiglabridin Modulates Paraoxonase 1 and Ameliorates Diet-Induced Obesity in Hyperlipidemic Mice
Biomolecules · 2023
Synthetic Glabridin Derivatives Inhibit LPS-Induced Inflammation via MAPKs and NF-κB Pathways in RAW264.7 Macrophages
Molecules · 2023
Vutiglabridin Alleviates Cellular Senescence Process of Dysfunctional Replication, Metabolic Regulation, and Circadian Clock in Primary Human Dermal Fibroblasts
2023
Paraoxonase-2 contributes to promoting lipid metabolism and mitochondrial function via autophagy activation
Scientific Reports · 2022
Vutiglabridin improves neurodegeneration in MPTP-induced Parkinson’s disease mice by targeting mitochondrial paraoxonase-2
2022
Safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of vutiglabridin: A first‐in‐class, first‐in‐human study
Clinical and Translational Science · 2022
Paraoxonase-2 contributes to promoting lipid metabolism and mitochondrial function via autophagy activation
2022
Synthetic glabridin derivatives mitigate steatohepatitis in a diet-induced biopsy-confirmed non-alcoholic steatosis hepatitis mouse model through paraoxonase-2
2021